Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors

NCT02697591 is registered in ClinicalTrials.gov with Incyte Biosciences International Sàrl as lead sponsor.

NCT NCT02697591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02697591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
Lead sponsor
Incyte Biosciences International Sàrl
Phase
Phase 1/2
Overall status
Completed
Start date
June 20, 2016
Completion date
December 16, 2019
Enrollment
100 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, metastatic cancer